Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value?
Bio-Rad Laboratories (BIO) has seen a sharp increase in its stock price over the last 90 days, despite recent flat revenue guidance and a significant long-term decline in shareholder return. The company is currently trading above its fair value estimate of $293, driven by robust order growth in biopharmaceutical research, but faces challenges from softer instrument demand. Investors are advised to review the data to form their own views on the company's valuation.
Bio-Rad Laboratories (NYSE: BIO) Q2 profit offset by H1 fair-value losses
Bio-Rad Laboratories reported flat net sales of $651.0 million in Q2 2026, with a significant net income of $371.4 million driven by a large fair-value gain on equity securities and a loan receivable, primarily related to its Sartorius investment. However, the first half of 2026 saw a net loss of $155.7 million due to a $280.2 million fair-value loss on these assets. The company announced a restructuring plan starting in July 2026, expected to incur $80-90 million in pre-tax charges through 2027, and maintains strong liquidity with $1.62 billion in cash and no borrowings on its credit facility.
Trading the Move, Not the Narrative: (BIO) Edition
This article provides an AI-generated analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), focusing on institutional trading strategies based on sentiment and price positioning. It outlines specific long and short trading strategies with entry zones, targets, and stop losses, along with a multi-timeframe signal analysis for near, mid, and long-term horizons. The analysis emphasizes strong near and mid-term sentiment, suggesting potential for extended positive momentum.
Bio-Rad Laboratories EVP Eva Anette Engelhardt Reports Restricted Stock Unit Vesting and Share Sale
Eva Anette Engelhardt, EVP and President of Bio-Rad Laboratories' Clinical Diagnostics Group, recently acquired 246 shares of Class A common stock through restricted stock unit vesting. Concurrently, she sold 89 shares at $314.46 each. This transaction offers transparency into executive compensation and stock ownership practices at the company.
Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide
Bio-Rad Laboratories (BIO) stock has declined 57.1% over five years, yet its current price of US$301.70 appears fairly valued according to Discounted Cash Flow (DCF) estimates which suggest an intrinsic value of $291 per share. However, its P/E ratio of 47.8x is higher than the Life Sciences industry average of 38.0x, indicating it might be overvalued based on earnings. The launch of Vericheck ddPCR kits could support future demand, but investors are already paying a premium.
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Bio-Rad Laboratories, Inc. Class A stocks, sorted by market value. It provides key financial data for each ETF, including issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year total return. The information aims to help investors identify opportunities and understand the risk profiles associated with these ETFs.
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate
Bio-Rad Laboratories (BIO) has launched new QX700 System-compatible Vericheck ddPCR Kits for quality control in cell and gene therapy, potentially impacting investor assessment of the stock. While the company's shares show modest recent momentum and analyst targets are largely met, Simply Wall St's narrative suggests a fair value of $293, making the current price of $296.11 slightly overvalued. The fair value assessment is based on strong recurring consumables sales and an optimistic earnings multiple, though softer instrument demand and policy shifts in China pose potential challenges.
(BIO) Volatility Zones as Tactical Triggers
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO) using AI models, identifying a neutral sentiment across all time horizons. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis highlights an exceptional 37.5:1 risk-reward setup, targeting a 10.8% gain against a 0.3% risk.
Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued
Bio-Rad Laboratories (BIO) has experienced recent stock momentum, with shares up 6.5% over the past week, although it's still down 54.9% over five years. The stock currently trades slightly above its narrative fair value of $293, driven by expectations of growth from its ddPCR platforms and Stilla Technologies acquisition. Despite this, the company faces challenges from softer instrument demand and Clinical Diagnostics headwinds in markets like China, making its valuation appear stretched when considering its P/E ratio of 47.7x compared to a fair ratio of 16.7x.
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449)
This article provides an overview of Bio-Rad Laboratories, Inc. Class B (LSX:862449) financial data, analyst estimates, and frequently asked questions. It details past earnings, revenue, net income, and future earnings expectations, along with share price forecasts from analysts. The report also covers employee count and EBITDA information for the company.
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW)
This article provides financial actuals and estimates for Bio-Rad Laboratories, Inc. Class B (FWB: BUW), detailing income statement, balance sheet, cash flow, and valuation metrics. It includes analyst forecasts, historical price movements, earnings reports, dividend policy, employee count, and EBITDA figures. The information is designed to help investors research and compare performance trends.
Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO)
This article provides an overview of Bio-Rad Laboratories, Inc. (NYSE: BIO) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for its future price, and information regarding upcoming earnings reports and dividends.
Price-Driven Insight from (BIO) for Rule-Based Strategy
This article provides a price-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It identifies a significant risk-reward short setup and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story
Bio-Rad Laboratories recently reported improved financial results with year-over-year revenue and net profit growth, yet institutional investors, notably First Eagle Investment, have significantly reduced their holdings. This divergence between strengthening financials and declining institutional ownership, alongside neutral to weak technical indicators, prompts questions about the investment narrative. The article suggests that while operational performance is improving, market confidence for BIO may remain fragile, despite a projected fair value of $293.00.
(BIO) as a Liquidity Pulse for Institutional Tactics
This article provides a detailed analysis of Bio-Rad Laboratories Inc. Class A (NYSE: BIO), highlighting its potential as a liquidity pulse for institutional tactics. It identifies a strong risk-reward setup targeting a 12.2% gain against 0.3% risk and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal analysis, indicating strong near-term and mid-term sentiment for the stock.
(BIO) as a Liquidity Pulse for Institutional Tactics
The article analyzes Bio-Rad Laboratories Inc. Class A (NYSE: BIO) with a focus on institutional trading strategies. It highlights a strong sentiment, an exceptional risk-reward setup targeting a 12.2% gain, and provides AI-generated trading signals for various time horizons and risk profiles. The analysis includes position trading, momentum breakout, and risk-hedging strategies, alongside support and resistance levels.
[144] BIO-RAD LABORATORIES, INC. SEC Filing
This SEC Filing (Form 144) for Bio-Rad Laboratories, Inc. (BIO) discloses a proposed sale of 700 shares of Class A Common stock by Alice Schwartz, acquired via donation on December 10, 2018. The aggregate market value of these shares is $219,296.44, to be sold on the NYSE on or after May 28, 2026, through Wells Fargo Clearing Services. The filing indicates a neutral impact and sentiment.
Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO)
Morgan Stanley Smith Barney LLC has filed a Rule 144 notice to sell 550 shares of Bio-Rad Laboratories (BIO). The filing indicates two restricted stock lots, dated July 25, 2025 (157 shares) and September 6, 2025 (393 shares), with the notice itself filed on May 11, 2026. This SEC filing signals an intent to sell restricted shares rather than a confirmed sale.
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Its Recent 16% Weekly Surge?
Bio-Rad Laboratories (BIO) recently experienced a 16.2% weekly surge, prompting a re-evaluation of its stock valuation. According to Simply Wall St's analysis, the company scores 2 out of 6 on its valuation framework and is considered fairly valued by a Discounted Cash Flow (DCF) model, with an estimated intrinsic value of $288.45 per share against a market price of $287.74. However, its P/E ratio of 45.62x, compared to a Fair Ratio of 15.53x, suggests the stock is overvalued based on earnings multiples.
Bio-Rad Laboratories, Inc. Class B Trade Ideas — BOATS:BIO.B
This article aggregates trade ideas for Bio-Rad Laboratories, Inc. (BIO.B) from various traders on TradingView. Ideas range from long positions based on fundamental analysis and technical indicators like the 100 EMA and RSI, to short positions anticipated after a technical break. ValuEngine also upgraded its rating for BIO.B to a BUY.
Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus
Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, signaling potential pressure for operational, governance, or portfolio changes. This move comes as Bio-Rad faces a mixed share price record and holds a substantial stake in Sartorius. Investors are anticipating proposals from Elliott regarding operational shifts, board changes, or actions concerning Bio-Rad’s Sartorius holding, alongside renewed analyst interest and expectations for margin improvements.
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories
Activist investor Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, Inc. and plans to advocate for improved share performance. Bio-Rad's substantial investment in Sartorius, valued at approximately $5 billion, is a key focus for Elliott, representing a significant portion of Bio-Rad's market capitalization. Despite a recent decline in Bio-Rad's share price and slight earnings miss, the company's turnaround potential and the value of its Sartorius stake could make it an attractive acquisition target.
How Investors Are Reacting To Bio-Rad Laboratories (BIO) As RBC Sees Margin Upside Under New Leadership
RBC Capital has restarted coverage of Bio-Rad Laboratories (BIO) with an Outperform rating, anticipating improved margins under new leadership and a sales recovery by 2027. This positive outlook is supported by recent share repurchases and strategic platform rollouts, reinforcing the importance of margin repair as a key near-term catalyst. However, investors should remain aware of potential risks from prolonged weakness in research and clinical demand.
Bio-Rad Laboratories, Inc. Class B Trade Ideas — LS:862449
This article compiles various trade ideas and analyses for Bio-Rad Laboratories, Inc. (LS:862449, NYSE:BIO) from different users on TradingView. It includes both long and short positions based on technical indicators like RSI, EMA, and pivot points, as well as fundamental analysis and analyst ratings. The ideas reflect different strategies and market outlooks for the company's stock.
Number of shareholders of Bio-Rad Laboratories, Inc. Class B – LS:862449
This article provides information about the number of shareholders for Bio-Rad Laboratories, Inc. Class B (LS:862449). It appears to be a page from TradingView, presenting financial data and market information for the company. The core content seems to be a placeholder for shareholder data, alongside various navigation and informational links.
About Us | Oil & Gas Journal - Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) Stock Quote
This article provides detailed stock information for Bio-Rad Laboratories, Inc. (NYSE:BIO), including its current price, trading volume, and performance metrics. It also lists recent news headlines related to the company, focusing on earnings reports, investor conferences, and other financial updates. The page also serves as an "About Us" section for Oil & Gas Journal, outlining its mission to cover the oil and gas industry.
(BIO) Movement as an Input in Quant Signal Sets
This article provides an analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating weak near and mid-term sentiment but a positive long-term outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report highlights AI-generated signals for support and resistance levels across different time horizons.
A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut
Bio-Rad Laboratories (BIO) experienced a Q1 2026 net loss of US$527.1 million and reduced revenue outlook, yet Simply Wall St's analysis suggests the stock is 19.9% undervalued with a fair value of $321.25. This valuation is based on expected growth in molecular diagnostics and precision medicine, driven by new product launches and acquisitions, despite current challenges like weaker bioprocessing demand and gross margin pressures. Investors are advised to consider both the narrative of undervaluation and the cautious P/E ratio, which currently stands at 40.8x compared to a fair ratio of 15.3x.
Bio-Rad Laboratories Inc. Class A (BIO) Stock Price | Live Quotes & Charts | NYSE
This page provides live quotes and charts for Bio-Rad Laboratories Inc. Class A (BIO) stock on the NYSE, showing a current price of $254.32, down $3.00 (-1.17%). It notes that there are no analyst ratings or earnings information currently available for the company. The page also includes an advertisement for options trading skills and a form to sign up for daily trade alerts.
Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO
This article provides a list of recent news and press releases concerning Bio-Rad Laboratories, Inc. (NYSE: BIO), including financial results disclosures, management changes, and conference participation announcements. It covers events from early 2023 through mid-2024, highlighting the company's continuous engagement with investors and the public. The stock's performance on the day of the article's crawl is also noted.
Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives
Bio-Rad Laboratories (BIO) reported a Q1 2026 basic EPS loss of US$19.55, despite an increase in quarterly revenue. This volatility in earnings, with net income swinging from a US$720 million gain to a US$527 million loss, raises concerns about the company's profit stability. While trailing twelve-month figures show a return to profit, modest growth forecasts and a 41x P/E ratio suggest a cautious outlook for investors.
Bio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes
Bio-Rad Laboratories (NYSE:BIO) has issued a cautious revenue outlook for 2026, citing a material impact from geopolitical disruptions in the Middle East, which led to a quarterly net loss of US$527.1 million despite sales being in line with guidance. The company plans to counter these headwinds through the Stilla acquisition, expected to be accretive within the year, and by focusing on business efficiency measures and high-margin areas like ddPCR technology and process chromatography. While analysts note the stock trades below its fair value, investors are advised to monitor the integration of Stilla, cost management, and the consistency of future earnings.
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss
Bio-Rad Laboratories (BIO) reported Q1 2026 revenue of $592.1 million, a 1.1% increase year-over-year, and a strong operating profit increase. Despite improved operating performance and cash flow, the company posted a deeply negative diluted EPS of -19.55 due to a large GAAP net loss of $527.1 million, missing analyst estimates for both revenue and EPS.
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss
Bio-Rad Laboratories (BIO) reported Q1 2026 revenue of $592.1 million, a 1.1% increase year-over-year, which was slightly below consensus estimates. Despite improving operating performance and stronger operating cash flow, the company recorded a large GAAP net loss of $527.1 million, resulting in a deeply negative diluted EPS of -19.55, significantly missing analyst estimates. The report also highlights hedge fund activity in BIO stock and recent government contracts awarded to the company.
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call
Bio-Rad Laboratories reported a 1.1% increase in net sales for Q1 2026, but a 4.2% decrease on a currency-neutral basis, primarily due to geopolitical conflicts in the Middle East and challenges in academic funding. The company adjusted its full-year 2026 guidance to between -3% and +0.5% currency-neutral revenue growth. Despite the headwinds, Bio-Rad is focusing on innovation, particularly in its digital PCR product line which saw 24% instrument revenue growth, and aims for mid-teens operating margins in the near term through operational efficiencies and disciplined M&A.
Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding
Bio-Rad Laboratories' EVP and CFO Roop Kalyan Lakkaraju acquired 1,078 shares of Class A common stock through RSU vesting on April 24, 2026. To cover tax obligations, 420 shares were disposed of at $287.84 per share, resulting in a net increase in direct holdings. After these transactions, Lakkaraju directly holds 2,563.895 Class A shares and has 2,156 restricted stock units remaining.
Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes
Bio-Rad Laboratories' EVP and General Counsel, Courtney C. Enloe, acquired 186 shares of Class A common stock through the vesting of restricted stock units (RSUs) on April 24, 2026. She subsequently had 77 shares withheld to cover tax obligations. After these transactions, her direct holdings of Class A shares increased to 826.777, and her remaining RSU balance from an original 744-unit grant is 372 units.
Bio-Rad Laboratories, Inc. Amends 2017 Incentive Award Plan and Updates Entity Information in April 2026 8-K Filing
Bio-Rad Laboratories, Inc. announced key developments from its 2026 Annual Meeting. Shareholders approved significant amendments to the 2017 Incentive Award Plan, including an increase in the share reserve and an extension of the plan's expiration date. Additionally, all nominated directors were elected, KPMG LLP was ratified as the independent auditor, and a shareholder proposal concerning the company's dual-class capital structure was not approved, maintaining the existing governance.
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes
Bio-Rad Laboratories' stockholders approved an amended 2017 Incentive Award Plan at their April 21, 2026 annual meeting, increasing reserved shares by 335,000 and extending the plan to March 18, 2036. All nominated directors were elected, KPMG LLP was ratified as auditor, and executive compensation received majority support in an advisory vote. A proposal regarding the company's dual-class capital structure did not pass.
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and gains 369 new units
Jeffrey L. Edwards, a director at Bio-Rad Laboratories (NYSE: BIO), exercised 407 restricted stock units (RSUs) into common shares and received an additional grant of 369 new RSUs. This transaction increased his direct holdings of Bio-Rad Class A common stock to 715 shares, while the 407 previously held RSUs were fully converted. The newly granted RSUs will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
Greg K. Hinckley adds Bio-Rad (BIO) shares through RSU vesting and grant
Bio-Rad Laboratories director Greg K. Hinckley increased his direct equity stake through the vesting of 407 restricted stock units (RSUs) into common stock and a new grant of 369 RSUs on April 21, 2026. Following these transactions, Hinckley directly holds 1,215 shares of Class A common stock. The newly granted RSUs will vest 100% on the earlier of their first anniversary or the company’s next annual meeting of stockholders.
Bio-Rad (BIO) director Arnold Pinkston gains shares, receives new RSU grant
Bio-Rad Laboratories, Inc. director Arnold A. Pinkston reported routine equity compensation, acquiring 407 shares of Class A common stock from vested restricted stock units (RSUs). After this transaction, his direct common stock holdings total 715 shares. Additionally, Pinkston received a new grant of 369 restricted stock units, which will vest 100% on the earlier of one year from the grant date or the company's next annual meeting of stockholders.
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and receives 369-unit grant
Bio-Rad Laboratories director Melinda Litherland engaged in routine equity compensation activities, exercising 407 restricted stock units (RSUs) into common stock, bringing her total direct holdings to 715 shares. Concurrently, she received a new grant of 369 RSUs, which will vest 100% on the earlier of the first anniversary of the grant date or the company's next annual meeting of stockholders. These transactions, reported on a Form 4 SEC filing, are considered neutral in impact and sentiment, aligning her compensation with future company performance.
Why (BIO) Price Action Is Critical for Tactical Trading
This article analyzes Bio-Rad Laboratories Inc. Class A (NYSE: BIO) with a focus on its price action for tactical trading, driven by predictive AI. It highlights strong sentiment across all horizons, identifies a mid-channel oscillation pattern, and notes an exceptional risk-reward short setup. The analysis provides specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels.
Understanding Momentum Shifts in (BIO)
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating a neutral near-term sentiment amidst mid and long-term strength. It highlights a significant 41.8:1 risk-reward setup targeting a 12.0% gain versus 0.3% risk. The analysis also provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Artisan Mid Cap Value Fund Sold Bio-Rad Laboratories (BIO) in Q4
Artisan Mid Cap Value Fund divested its position in Bio-Rad Laboratories (NYSE: BIO) during Q4 2025, according to its investor letter. While acknowledging Bio-Rad's business, the fund expressed concern over the CEO's capital allocation strategy, specifically regarding large M&A. The proceeds from the sale were used to purchase Revvity.
Avoiding Lag: Real-Time Signals in (BIO) Movement
This article from Stock Traders Daily discusses real-time trading signals for Bio-rad Laboratories Inc. Class A (NYSE: BIO). It highlights the stock's strong near-term sentiment while noting potential breakdowns and elevated downside risk. The analysis includes three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for different horizons.
Discipline and Rules-Based Execution in BIO Response
This article analyzes Bio-Rad Laboratories Inc. (NYSE: BIO) with AI-generated trading strategies. It highlights weak near-term sentiment but strong long-term prospects, identifying key support and resistance levels. The analysis provides specific entry and exit points for position trading, momentum breakout, and risk hedging strategies, emphasizing disciplined, rules-based execution.
Behavioral Patterns of BIO and Institutional Flows
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO) with AI-generated signals and strategies. It identifies a near-term strong sentiment, mid-term neutrality, and long-term positive bias, noting a current breakdown with elevated downside risk. The report provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies.
Is It Time To Reconsider Bio-Rad Laboratories (BIO) After Its Prolonged Share Price Slump
Bio-Rad Laboratories (BIO) has experienced a significant share price slump over the past five years, prompting a re-evaluation of its valuation. Despite the historical decline, a Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 33.4%, with an intrinsic value of about $418.03 per share compared to its current trading price of around $278.44. Additionally, its P/E ratio of 9.89x is considerably lower than the Life Sciences industry average, further indicating it may be trading below its fair value.
